Methotrexate and Rheumatoid Arthritis: Current Evidence Regarding Subcutaneous Versus Oral Routes of Administration

Abstract

Methotrexate (MTX) is still considered the drug of choice in rheumatoid arthritis (RA) management. Comparing subcutaneous (MTX SC) and oral (MTX OR) routes of administration is important to optimize the everyday therapeutic strategy in the real-life setting. This review summarizes scientific evidence currently available on this topic. As shown by pharmacokinetic studies, at the same dose level, bioavailability of MTX SC is significantly higher and less variable than that of MTX OR. This difference is even more pronounced for medium-to-high dosages (i.e., >15 mg/week). With regard to clinical response (Disease Activity Score-28, American College of Rheumatology Criteria), randomized, double-blind studies and retrospective or longitudinal analyses in real-life settings showed that MTX SC is more effective than MTX OR. This is true both in MTX-naive patients with early RA, and in patients who switch from MTX OR to MTX SC due to previous treatment failure, lack of efficacy and/or adverse events. Finally, MTX SC has a better tolerability profile than MTX OR, with fewer gastroenterological side effects. Delaying the use of more expensive biological therapies by switching from MTX OR to MTX SC in non-responders might provide cost savings, with relevant implications in the management of patients with RA.FundingAlfa Wassermann.Electronic supplementary materialThe online version of this article (doi:10.1007/s12325-016-0295-8) contains supplementary material, which is available to authorized users.

Determinants for drug survival of methotrexate in patients with psoriasis, split according to different reasons for discontinuation: results of the prospective MTX-CAPTURE

“…When discussing the route of MTX administration, several studies recommend the subcutaneous use of MTX over oral use in order to improve its efficacy and/or to reduce its side‐effects . In our study, MTX was administered orally for most patients ( n = 74, 84%).…”

Using subcutaneous methotrexate to prolong duration of methotrexate therapy in rheumatoid arthritis

“…Longer monotherapy duration in older patients may be due to less aggressive treatment of RA in elderly patients (18)(19)(20)(21). We also found that the use of SC MTX was associated with increased frequency of GI symptoms, contrary to the findings of other analyses (22). This may be related to the higher bioavailability of SC MTX when compared to oral MTX or other confounders such as additional medications or illnesses that we were unable to account for in our model (15,23).…”

Novel nano therapeutic materials for the effective treatment of rheumatoid arthritis-recent insights

“…RA can be effectively managed by anti-rheumatic drugs (such as, Methotrexate (MTX), leflunomide, sulfasalazine, and hydroxy-chloroquine [14] combined with/without different non-steroidal anti-inflammatory drug (aspirin, celecoxib, diclofenac, ibuprofen, indomethacin, ketoprofen etc.,) among these drugs, MTX was considered as an effective drug since 1980 [15]. Inspite, we are also developing a formulation using MTX with another drug combination for the effective treatment of RA.…”